Chronic Pain, Functional Abdominal Pain Syndrome, Low Back Pain, Migraine, Pelvic Pain
Conditions
Brief summary
The purpose of this study is to perform a first in man study with VCR stimulation of the belly and back for patients with chronic pain conditions including pelvic pain, functional abdominal pain, or low back pain. This study will also examine VCR stimulation of the temporal region for patients with migraine with or without aura. Additional goals of the study will be to determine the safety, tolerability, and acceptability of VCR stimulation for the treatment of these pain conditions.
Interventions
DEVICEVibrotactile Stimulation
Application of VCR stimulation to the belly and back of patients with pelvic pain, functional abdominal pain, or low back pain or to the temporal region for patients with migraine.
DEVICESham Stimulation
Low-frequency sham of VCR stimulation
Sponsors
Stanford University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age greater than or equal to 18 years old. * Diagnosis of either chronic pelvic pain, functional abdominal pain, axial low back pain, or migraine with or without aura of at least 3 months duration. * English speaking * Ability and willingness to complete questionnaires and in-person assessments * Current average daily pain score of greater than or equal to 4 on the Numeric Rating Scale of Pain (0-10 scale) * For patients with migraine diagnosis they must report at least 2 headaches in the baseline headache diary in the 30 days preceding randomization.
Exclusion criteria
* Any conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status) * Any significant psychiatric problems, including acute confusional state (delirium), ongoing psychosis, or clinically significant depression * Any suicidality as assessed by answer of greater than 0 on question 9 the PHQ-9 assessing suicidal thoughts. * Any current illicit drug or alcohol abuse. * Any history of recurrent or unprovoked seizures. * Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. * Pregnancy, breast-feeding or lack of reliable contraception * Changes in pain medications in the previous 4 weeks * Implanted electrical stimulation device. * Skin infection over stimulation sites. * Any pain interventions in the preceding 6 weeks (epidural steroid injection, sympathetic block, peripheral nerve block, lumbar medial branch blocks) Any botulinum toxin injection in the previous 3 months * For patients with migraine diagnosis additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment Responder | 30 days | Proportion of subjects in the treatment vs. placebo groups that are responders with greater than or equal to 50% reductions in average pain (in the primary pain area) comparing the average pain score from the 7-day baseline diary pre-treatment to the average scores based on 7-day diaries at the end of the primary outcome interval |
| Change in Opioid Use | 30 days | Change in opioid use in daily oral morphine equivalents from the average 7-day baseline use to the post-treatment use in the 7 days at the end of the primary outcome interval. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | 60 days | The proportion of adverse events occurring in the treatment vs. placebo groups |
| Secondary Treatment Response After Crossover | 60 days | The proportion of subjects in the treatment vs. placebo groups that are responders at the end of 60 days comparing the average pain score from the 7- day baseline diary pre-treatment to the reported pain score at the end of the 60 day interval. |
| Change in monthly migraine days | 30 days | For patients with migraine, change in monthly migraine days between the 30 days before randomization and the end of the primary outcome interval. |
| Treatment Engagement | 30 days | Treatment engagement is defined as participation in \>50% of home treatment sessions. |
| Treatment Initiation | 30 days | Treatment initiation is defined as participation in at least 1 home treatment session. session. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORJennifer M Hah, MD
Stanford University
Outcome results
None listed